Drugs / anti-BCMA CAR-T

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT04637269 Nov 2020 → Nov 2021 plasma cell myeloma Xinqiao Hospital of Chongqing Unknown No outcome recorded
Phase 27 trials
Phase 2 NCT06880393 Mar 2025 → Mar 2027 expected plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2 NCT06793449 Feb 2025 → Dec 2026 expected plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2 NCT05979363 Aug 2023 → Jul 2026 overdue plasma cell leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2 NCT05846737 May 2023 → May 2025 plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Withdrawn No outcome recorded
Phase 2 NCT05870917 May 2023 → Jun 2026 overdue plasma cell leukemia Institute of Hematology & Blood Diseases Hospital, China Active not recruiting No outcome recorded
Phase 2 NCT05850286 Apr 2023 → Apr 2026 overdue plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Active not recruiting No outcome recorded
Phase 2 NCT05860036 Apr 2023 → Jun 2025 overdue plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as anti-BCMA CAR-T ClinicalTrials.gov intervention name — accepted as the source's own label NCT05860036
7

NCT05979363

NCT05870917

NCT05850286

NCT05846737

NCT06793449

NCT04637269

NCT06880393

Modality Cell therapy “anti-BCMA CAR-T cell therapyNCT04637269
Route Intravenous “infusion intravenously” NCT05846737